Shay Boloor(@StockSavvyShay):$QURE is down ~70% after its Huntington’s gene therapy showed slower disease progression at 48 months but failed to reach statistical significance. Another function test still looked better but missing data and serious brain inflammation in 17% of high dose patients made the update much harder to trust.

Shay Boloor

@StockSavvyShay

Chief Market Strategist @FuturumEquities | Regular on @Reuters, @YahooFinance, @Bloomberg, @FoxBusiness, @SchwabNetwork & @Forbes | NIA

Joined February 2019

335 Following 460.5K Followers

Shay Boloor@StockSavvyShay

2026.09.29 11:23

$QURE is down ~70% after its Huntington’s gene therapy showed slower disease progression at 48 months but failed to reach statistical significance. Another function test still looked better but missing data and serious brain inflammation in 17% of high dose patients made the update much harder to trust.